跳转至内容
Merck

O1385

Sigma-Aldrich

Ozagrel hydrochloride hydrate

≥98% (HPLC), solid

别名:

(E)-3-[4-(Imidazol-1-ylmethyl)phenyl]propenoic acid hydrochloride hydrate, OKY-046

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C13H12N2O2 · HCl · xH2O
CAS号:
分子量:
264.71 (anhydrous basis)
MDL號碼:
分類程式碼代碼:
12352200
PubChem物質ID:
NACRES:
NA.77

品質等級

化驗

≥98% (HPLC)

形狀

solid

儲存條件

desiccated

顏色

white to off-white

溶解度

H2O: soluble

儲存溫度

room temp

SMILES 字串

O.Cl.OC(=O)\C=C\c1ccc(Cn2ccnc2)cc1

InChI

1S/C13H12N2O2.ClH.H2O/c16-13(17)6-5-11-1-3-12(4-2-11)9-15-8-7-14-10-15;;/h1-8,10H,9H2,(H,16,17);1H;1H2/b6-5+;;

InChI 密鑰

OWIZTYOMGVTSDP-TXOOBNKBSA-N

應用

Ozagrel hydrochloride hydrate has been used as a thromboxane synthase inhibitor:
  • in high cholesterol-diet rats (HC) to test its effect on arteriolar constriction
  • to pre-treat mice to test its effect on lipopolysaccharide (LPS)-induced behavioral changes
  • to test its effect on arteriolar vasoconstriction in hyperglycemic mice

生化/生理作用

Ozagrel is useful in treating lacunar and thrombotic stroke. It blocks vasoconstriction and platelet aggregation. Ozagrel aids in improving the prostacyclin (PGI2)/ thromboxane A2 (TXA2) in the acute phase of cerebral ischemia. It improves endothelial dysfunction in L-methionine-induced hyperhomocysteinemia (HHcy)-induced vascular cognitive impairment and dementia (VCID).
Ozagrel is a selective thromboxane A2 synthase (TXA2) inhibitor.

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 2

閃點(°F)

Not applicable

閃點(°C)

Not applicable

個人防護裝備

Eyeshields, Gloves, type N95 (US)


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

K Shinagawa et al.
British journal of pharmacology, 131(2), 266-270 (2000-09-19)
1. The purpose of this study was to investigate the involvement of thromboxane A(2) (TXA(2)) in the cough response in a guinea-pig cough model. Here, we describe results obtained using a selective TXA(2) synthetase inhibitor, ozagrel, and a selective TXA(2)
Takayuki Matsumoto et al.
Atherosclerosis, 205(1), 87-95 (2008-12-30)
Thromboxane A(2) (TXA(2)) is thought to contribute to the development of diabetic complications. We tested the hypothesis that the impaired endothelial function seen in Otsuka Long-Evans Tokushima Fatty (OLETF) rats (a type 2 diabetic model) might be improved by chronic
Yoichi Ishitsuka et al.
Journal of pharmacological sciences, 111(2), 211-215 (2009-09-29)
This study examined the effect of ozagrel, a thromboxane A(2) synthase inhibitor, on the accumulation of leucocytes and chemokine mRNA expression in lungs experimentally injured using oleic acid (OA). OA injection into guinea pigs rapidly increased thromboxane A(2) generation and
Seungjun Lee et al.
Microvascular research, 76(3), 217-223 (2008-08-23)
Retinal blood flow decreases early in the progression of diabetic retinopathy; however, the mediators and mechanisms responsible for this decrease have yet to be determined. In this study, diabetes was induced by streptozotocin in rats, and retinal blood flow was
Sang In Park et al.
Brain research, 1599, 85-92 (2015-01-04)
We investigated the neuroprotective properties of single doses of minocycline and ozagrel when administered prior to stroke. Male Sprague-Dawley rats were assigned randomly to one of the following groups: (1) control (Con) group (n=10), (2) minocycline (Mino) group (n=10), (3)

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门